首页|期刊导航|沈阳医学院学报|新型赖氨酸酰化修饰调控肿瘤耐药的研究进展

新型赖氨酸酰化修饰调控肿瘤耐药的研究进展OA

Research advances in the regulation of cancer therapy resistance by novel lysine acylations

中文摘要英文摘要

肿瘤耐药是限制恶性肿瘤治疗获益和患者长期生存的重要因素.近年来,乳酰化、琥珀酰化和巴豆酰化等新型赖氨酸酰化修饰逐渐被证实参与肿瘤耐药.肿瘤代谢重编程可通过改变酰基供体生成及酰化调控酶活性,动态调节组蛋白和非组蛋白酰化状态.组蛋白酰化主要通过重塑染色质状态和耐药相关转录程序,影响细胞可塑性、DNA损伤修复及肿瘤免疫;非组蛋白酰化则通过调节蛋白稳定性、酶活性、亚细胞定位及分子相互作用,参与细胞死亡、代谢适应和免疫逃逸.此外,新型酰化还可与磷酸化、泛素化等翻译后修饰发生交互,共同影响耐药相关蛋白功能及信号传导.本文系统综述新型赖氨酸酰化的生物学基础、肿瘤耐药机制及潜在干预策略,为深入认识肿瘤非遗传性耐药和探索联合治疗靶点提供参考.

Cancer therapy resistance is a major factor limitting sustained therapeutic benefit and long-term survival in patients with cancer.In recent years,novel lysine acylations,including lactylation,succinylation,and crotonylation,have increasingly been shown to participate in cancer therapy resistance.Metabolic reprogramming in tumor cells can dynamically regulate histone and non-histone acylation by altering acyl donor generation and the activity of acylation-regulating enzymes.Histone acylation primarily affects cellular plasticity,DNA damage repair,and antitumor immunity by remodeling chromatin states and resistance-related transcriptional programs,whereas non-histone acylation contributes to cell death,metabolic adaptation,and immune escape by regulating protein stability,enzymatic activity,subcellular localization,and molecular interactions.In addition,novel acylations can interact with other post-translational modifications,such as phosphorylation and ubiquitination,thereby jointly influencing the functions of resistance-related proteins and signaling pathways.This review systematically summarizes the biological basis of novel lysine acylations,their mechanisms in cancer therapy resistance,and potential intervention strategies,with the aim of providing a reference for further understanding the non-genetic mechanisms of cancer therapy resistance and identifying targets for combination therapy.

陈思宏;王立辉

沈阳药科大学临床药学院,辽宁 沈阳 110016沈阳药科大学临床药学院,辽宁 沈阳 110016

医药卫生

新型赖氨酸酰化肿瘤耐药代谢重编程翻译后修饰表观遗传调控

novel lysine acylationscancer therapy resistancemetabolic reprogrammingpost-translational modificationepigenetic regulation

《沈阳医学院学报》 2026 (5)

449-458,10

国家自然科学基金项目(No.82373157No.82607678)

10.16753/j.cnki.1008-2344.2026.05.001

评论